




RealRate

PHARMACEUTICAL 2024

Transcode Therapeutics Inc
Rank 282 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Transcode Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Transcode Therapeutics Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 6.8% points. The greatest weakness of Transcode Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 158% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	4,455
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,491
Liabilities, Non-Current	38
Other Assets	594
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	872
Other Revenues	0
Property and Equipment	121
Research and Development	12,264
Selling, General and Administrative Expense	7,155

Output Variable	Value in 1000 USD
Assets	5,170
Liabilities	3,529
Expenses	19,419
Revenues	0
Stockholders Equity	1,641
Net Income	-18,546
Comprehensive Net Income	-18,546
BaseVar	14,495
ECR before LimitedLiability	-344%
Economic Capital Ratio	55%